News archive for Mohn Cancer Research Laboratory
In an interview with journalist Marit Aaby Vebenstad (published 28.06.2022 in the Norwegian oncology journal Brystkreft), Per Eystein Lønning from Mohn Cancer Research Laboratory talks about the promising effect of Lynparza as monotherapy in the treatment of triple negative breast cancer in the clinical trial Petremac.
Norwegian newspaper Dagbladet (04.06.2022 (digital edition) and 21.06.2022 (paper edition)) and Swedish newspaper Expressen (12.06.2022) both mention a research project that is a collaboration between the Breast Cancer Group at Mohn Cancer Research Laboratory and the Women's Health Initiative (WHI) in USA. The research study describes a new type of mechanism that is triggered during early... Read more
In an interview with journalist Julie Kalveland from Dagens Medisin (04.06.2022) Professor Per Eystein Lønning shares the most important findings from a Norwegian-American collaboration study on BRCA1-methylation in breast and ovarian cancer. These findings were presented orally by Lønning at ASCO (03.06.2022).